Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* is a healthy Japanese male or female ≥20 years of age at time of randomization~* male participants must agree to be abstinent or use contraception during the intervention period and for ≥30 days after the last dose of study intervention~* female participants must not be pregnant or breastfeeding, and is either:~* not a woman of childbearing potential (WOCBP) or~* a WOCBP who agrees to remain abstinent or use contraception during the intervention period and for ≥30 days after the last dose of study intervention~Exclusion Criteria:~* has a history of invasive pneumococcal disease (IPD) within 3 years of Day 1~* has a known hypersensitivity to any vaccine components~* has impaired immunological function~* has a coagulation disorder~* had a recent febrile illness (axillary temperature ≥37.5°C or equivalent) within 72 hours before Day 1~* has a known malignancy that is progressing/requiring treatment~* has received, or is expected to receive, a pneumococcal vaccine outside the study protocol~* has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed the regimen for ≥30 days prior to Day 1~* is receiving immunosuppressive therapy~* has received any non-live vaccine from 14 days prior to Day 1 other than inactivated influenza vaccine~* has received any live vaccine from 30 days prior to Day 1~* has received a blood transfusion or blood products~* has participated in another clinical trial within 2 months of this study~* has clinically relevant drug or alcohol abuse~* has any condition that, in the opinion of the investigator, precludes participation in this study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- V116 (Type: EXPERIMENTAL): Participants receive a single 1.0 mL intramuscular (IM) injection of V116 on Day 1.
- PNEUMOVAX™23 (Type: ACTIVE_COMPARATOR): Participants receive a single 0.5 mL IM injection of PNEUMOVAX™23 on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).